Raylumis

RSS

tanezumab

Refused
This medicine was refused authorisation for use in the European Union.

Overview

The European Medicines Agency has recommended the refusal of the marketing authorisation for Raylumis, a medicine intended for the treatment of pain associated with osteoarthritis.

The Agency issued its opinion on 16 September 2021. The company that applied for authorisation, Pfizer Europe MA EEIG, may ask for re-examination of the opinion within 15 days of receiving the opinion.

This EPAR was last updated on 15/02/2022

Application details

Product details
Name
Raylumis
Active substance
Tanezumab
International non-proprietary name (INN) or common name
tanezumab
Therapeutic area (MeSH)
  • Osteoarthritis
  • Pain
Anatomical therapeutic chemical (ATC) code
N02
Application details
Marketing-authorisation applicant
Pfizer Europe MA EEIG 
Date of opinion
16/09/2021
Date of refusal of marketing authorisation
15/11/2021

Assessment history

How useful was this page?

Add your rating